KOMET-001 registrational trial in R/R NPM1-mutant AML achieved primary endpoint – – Alignment reached with FDA and EMA on key aspects of the KOMET-017 protocol including use of MRD-negative CR ...

Discover how next-generation kinase inhibitors are transforming clinical therapy byovercoming resistance and enhancing ...